Farmers Trust Co. decreased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,403 shares of the company’s stock after selling 611 shares during the period. Johnson & Johnson makes up 2.8% of Farmers Trust Co.’s investment portfolio, making the stock its 5th largest holding. Farmers Trust Co.’s holdings in Johnson & Johnson were worth $12,437,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. State Street Corp raised its position in Johnson & Johnson by 0.6% during the third quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after acquiring an additional 803,013 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 3.3% during the third quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Legal & General Group Plc raised its position in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after acquiring an additional 421,779 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available at this link. 0.35% of the stock is currently owned by corporate insiders.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. Johnson & Johnson’s revenue was down 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.13 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.95%. Johnson & Johnson’s dividend payout ratio (DPR) is 67.06%.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on JNJ. Citigroup lifted their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. SVB Leerink cut their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Atlantic Securities lifted their target price on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. Finally, Piper Sandler lowered their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.67.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Dave & Buster’s Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It’s No Stretch: Lululemon Could Break Out of its Range
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
